NCT00036790View on ClinicalTrials.gov

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

February 28, 2002

Primary Completion Date

October 31, 2005

Conditions
Breast CancerChronic Myeloproliferative DisordersColorectal CancerHead and Neck CancerLeukemiaLung CancerLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic/Myeloproliferative DiseasesProstate CancerSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

doxorubicin hydrochloride

DRUG

motexafin gadolinium

Trial Locations (2)

15232

Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh

53792

University of Wisconsin Comprehensive Cancer Center, Madison

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Wisconsin, Madison

OTHER

NCT00036790 - Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter